INTRODUCTION:Topiramate (TOP) blocks glutamate receptors and facilitates GABA (γ-aminobutyric acid) neurotransmission, effects that may facilitate smoking cessation. We compared the effects of behavioral counseling combined with (a) TOP, (b) TOP/nicotine patch (TOP/NIC), or (c) placebo (PLC) for smoking cessation. METHODS: We conducted a 10-week randomized trial in which subjects and research personnel were blinded to TOP versus PLC but not to the TOP/NIC patch condition. In groups receiving TOP, the medication dosage was titrated gradually up to 200 mg/day. The smoking quit date (QD) was scheduled after 2 weeks of medication treatment. NIC (21 mg) was started on the QD in subjects randomized to the TOP/NIC condition. The main outcome measure was the end-of-treatment, 4-week continuous abstinence rate (CAR; biochemically confirmed). RESULTS:Fifty-seven subjects were randomized to treatment. The 4-week CAR was 1 of 19 (5%) in the PLC group, 5 of 19 (26%) in the TOP group, and 7 of 19 (37%) in the TOP/NIC group (p = .056). Pairwise comparisons showed a difference between TOP/NIC and PLC (p = .042) and a nonsignificant difference between TOP and PLC (p = .18). The PLC group gained 0.37 lb/week, the TOP group lost 0.41 lb/week, and the TOP/NIC group lost 0.07 lb/week (p = .004). Pairwise comparisons showed a difference between TOP and PLC (p < .001) and between TOP/NIC and PLC groups (p = .035). Paresthesia was more frequent in subjects on TOP than PLC (p = .011). CONCLUSIONS: TOP, alone or in combination with the NIC, resulted in a numerically higher quit rate than PLC and decreased weight. A larger, PLC-controlled trial is needed to confirm these findings.
RCT Entities:
INTRODUCTION:Topiramate (TOP) blocks glutamate receptors and facilitates GABA (γ-aminobutyric acid) neurotransmission, effects that may facilitate smoking cessation. We compared the effects of behavioral counseling combined with (a) TOP, (b) TOP/nicotine patch (TOP/NIC), or (c) placebo (PLC) for smoking cessation. METHODS: We conducted a 10-week randomized trial in which subjects and research personnel were blinded to TOP versus PLC but not to the TOP/NIC patch condition. In groups receiving TOP, the medication dosage was titrated gradually up to 200 mg/day. The smoking quit date (QD) was scheduled after 2 weeks of medication treatment. NIC (21 mg) was started on the QD in subjects randomized to the TOP/NIC condition. The main outcome measure was the end-of-treatment, 4-week continuous abstinence rate (CAR; biochemically confirmed). RESULTS: Fifty-seven subjects were randomized to treatment. The 4-week CAR was 1 of 19 (5%) in the PLC group, 5 of 19 (26%) in the TOP group, and 7 of 19 (37%) in the TOP/NIC group (p = .056). Pairwise comparisons showed a difference between TOP/NIC and PLC (p = .042) and a nonsignificant difference between TOP and PLC (p = .18). The PLC group gained 0.37 lb/week, the TOP group lost 0.41 lb/week, and the TOP/NIC group lost 0.07 lb/week (p = .004). Pairwise comparisons showed a difference between TOP and PLC (p < .001) and between TOP/NIC and PLC groups (p = .035). Paresthesia was more frequent in subjects on TOP than PLC (p = .011). CONCLUSIONS: TOP, alone or in combination with the NIC, resulted in a numerically higher quit rate than PLC and decreased weight. A larger, PLC-controlled trial is needed to confirm these findings.
Authors: Cerstin Nickel; Claas Lahmann; Karin Tritt; Moritz Muehlbacher; Patrick Kaplan; Christian Kettler; Jakub Krawczyk; Thomas H Loew; Wolfhardt K Rother; Marius K Nickel Journal: J Affect Disord Date: 2005-08 Impact factor: 4.839
Authors: Susan L McElroy; Mark A Frye; Lori L Altshuler; Trisha Suppes; Gerhard Hellemann; David Black; Jim Mintz; Ralph Kupka; Willem Nolen; Gabriele S Leverich; Kirk D Denicoff; Robert M Post; Paul E Keck Journal: Bipolar Disord Date: 2007-06 Impact factor: 6.744
Authors: Robert Miranda; Hayley Treloar; Alexander Blanchard; Alicia Justus; Peter M Monti; Thomas Chun; Robert Swift; Jennifer W Tidey; Chad J Gwaltney Journal: Addict Biol Date: 2016-01-11 Impact factor: 4.280
Authors: Kelly E Dunn; Taylor F Marcus; Cynthia Kim; Jennifer R Schroeder; Ryan Vandrey; Annie Umbricht Journal: Nicotine Tob Res Date: 2015-10-17 Impact factor: 4.244
Authors: Robert M Anthenelli; Jaimee L Heffner; Esther Wong; Jessie Tibbs; Katie Russell; Melodie Isgro; Elizabeth Dinh; Chris Wehrle; Matthew J Worley; Neal Doran Journal: Alcohol Clin Exp Res Date: 2016-12-28 Impact factor: 3.455